This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

Claims 1 - 193(canceled).

194(new). A method of enhancing an immune response to an antigen in a human or animal, the method comprising administering to the human or animal by mucosal administration an antigen selected from the group consisting of diphtheria toxoid, influenza and rota virus antigen together with an immune response enhancing effective amount of an adjuvant consisting essentially of:

i) monoolein

ii) oleic acid and

iii) water

wherein the concentration of i) is from 0.1 g to 50 g per 100 ml of water, and the concentration of ii) is from 1 g to 50 g per 100 ml of water, and with the proviso that the percent weight ratio of i) in ii) is between 10 to 90.

195(new). The method according to claim194, wherein the purity of the monoolein is at least 90%.

196(new). The method according to claim 194, wherein the purity of monoolein is at least 95%.

197(new). A method according to claim 194, wherein the mucosal administration is to the mucosa of the nose, mouth, vagina, rectum or intestine.

198(new). A method according to claim 194, wherein the mucosal administration is to the mucosa of the nose.

199(new). A method of immunizing a human or animal, the method comprising administering to a human or animal by mucosal administration a vaccine composition comprising an adjuvant as defined in claim 194, and an immunogenic quantity of an antigen component selected from the group consisting of diphtheria toxoid, influenza and rota virus antigen.

200(new). The method according to claim 199, containing in 100 g of the final vaccine composition:

from 0.01 to 90 g antigen component selected from the group consisting of diphtheria toxoid, influenza or rota virus antigen,

from 1 to 20 g of monoolein,

from 1 to 20 g oleic acid,

from 0.01 to 99 g water,

from 0.01 to 99 g PBS or saline, and

optionally one or more excipients.

201(new). The method according to claim 199, wherein the vaccine composition comprises additional pharmaceutical excipients selected from the group consisting of preservatives, osmotic pressure controlling agents, pH-controlling agents, organics solvents, enzyme inhibitors, water absorbing polymers, absorption promoters and anti-oxidative agents.

202(new). A method according to claim 199, wherein the mucosal administration is to the mucosa of the nose, mouth, vagina, rectum or intestine.

203(new). A method according to claim 199, wherein administration is to the mucosa of the nose.